Markets

Ascendis Pharma Says COMP Of EMA Adopts Positive Opinion Recommending Maintenance Of Orphan Medicinal Product Designation For Once-Weekly TransCon CNP As Treatment For Achondroplasia In Children

Nov 6, 2026 · 08:02 AM ET· updated 1h ago

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending maintenance of orphan

Why It Matters

Ascendis Pharma got approval to keep a special status for a children's medicine. This special status helps smaller medicines get extra support and protection from regulators.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ASND252.08

-1.37 (-0.54%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.